Two Novel Therapies Show Promise for Neovascular AMD: Duravyu Insert and Ixo-vec Gene Therapy Demonstrate Safety and Efficacy in Phase 2 Trials
核心洞察
Duravyu intravitreal insert demonstrated noninferior visual acuity outcomes compared to aflibercept 2 mg control group over 2 years in the phase 2 DAVIO 2 trial.
The sustained-release device provided stable retinal morphology and worked effectively at stabilizing disease when administered after aflibercept initiation therapy.
Ixo-vec gene therapy showed excellent safety signals throughout a 4-year study period in the phase 2 LUNA trial for neovascular AMD (搜索).
Two innovative therapeutic approaches for neovascular age-related macular degeneration (搜索) (AMD) have shown encouraging results in recent phase 2 clinical trials, offering potential new treatment paradigms for this sight-threatening condition. Data presented at the American Academy of Ophthalmology meeting highlighted the performance of both a sustained-release drug delivery system and a gene therapy approach.
Duravyu Intravitreal Insert Shows Noninferiority to Standard Care
The phase 2 DAVIO 2 trial evaluated Duravyu (vorolanib intravitreal insert (搜索)) from EyePoint Pharmaceuticals in patients with neovascular AMD (搜索). According to Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic, patients who received Duravyu "had very good, stable visual acuity over the course of 2 years as well as stable retinal morphology, which was noninferior to the aflibercept 2 mg control group."
The sustained-release device demonstrated particular effectiveness when used sequentially after aflibercept therapy initiation. Stewart emphasized that the results "highlight the fact that this drug, when given after aflibercept initiation of therapy, really works well at stabilizing disease over time."
Gene Therapy Approach Demonstrates Long-term Safety Profile
The phase 2 LUNA trial investigated Ixo-vec (ixoberogene soroparvovec) from Adverum Biotechnologies, a gene therapy approach for neovascular AMD (搜索). The study's 4-year follow-up period provided crucial safety data for this novel therapeutic modality.
Stewart noted that Ixo-vec "showed excellent safety signals" throughout the extended study period, addressing what he considers the primary concern with gene therapy approaches. "That really, to me, is the No. 1 concern with gene therapy, even more so than the efficacy. Is it going to be safe?" he explained.
The safety profile remained favorable across multiple parameters, with Stewart reporting that concerns about "inflammation, [retinal pigment epithelium] damage, anything else that we might see" were not substantiated by the trial data. The gene therapy approach also demonstrated "excellent stability in terms of visual acuity" over the 4-year observation period.
Clinical Implications for AMD Treatment
Both therapeutic approaches represent potential advances in addressing the treatment burden associated with current neovascular AMD (搜索) management, which typically requires frequent intravitreal injections. The sustained-release technology of Duravyu and the long-acting nature of gene therapy could potentially reduce injection frequency while maintaining therapeutic efficacy.
The noninferiority results for Duravyu suggest that patients could achieve comparable visual outcomes to current standard-of-care treatments while potentially benefiting from extended dosing intervals. Meanwhile, the 4-year safety data for Ixo-vec provides important validation for the gene therapy approach in ophthalmology, particularly given the critical importance of long-term safety in treating a chronic condition affecting vision.